Keep in touch with meI'm using Intch to connect with new people. Use this link to open chat with me via Intch app
Work Background
University Hospital BaselVisiting Scientist, Cancer Biology and Therapy
Nov. 2021 - May. 2024Basel, Switzerland- Key results:
• Fostered a fruitful collaboration to study cancer stem cells (CSCs) and CSC biomarkers for the development of targeted therapies.
• Obtained clinically relevant insights through development of methods and techniques according to current trends and innovations (e.g. CRISPR-Cas9, omics, bioassays, 3D).
OncoRay - National Center for Radiation Research in OncologyVisiting Scientist, Cancer Biology and Therapy
Sep. 2021 - Oct. 2021Dresden, Saxony, Germany- Key results:
• Fostered an international collaboration to study cancer cell populations and biomarkers of therapy resistance in various cancer types which resulted in the development of key R&D methodologies (e.g. cancer stemness, bioassays, in vitro and in vivo testing).
ETH ZürichLeadership, Mentoring, Training, Tutoring at ETH Zurich & Paul Scherrer Institute
Oct. 2020 - Dec. 2023Zurich, Switzerland• Key results: - All my group or individual trainees successfully achieved their milestones, deepened their expertise, and grew personally. - Designed curriculum and projects according to personalized needs. • Groups: >100 students in General Chemistry (B.Sc. Biology, and Pharmaceutical Sciences); >60 trainees from various professional levels in Certificate of Advanced Studies (CAS) in Radiopharmacy. • Individually: designed and supervised personalized projects, and mentored >3 M. Sc. students in biology, cancer biology and therapy, pharmacology, academic skills (writing, reporting, presenting), supported fellow PhD team members.
Paul Scherrer Institut PSIDoctoral Candidate, Pharmacology, Biopharmaceuticals, Oncology, Targeted Therapies - ETH Zurich-PSI
Jul. 2020 - Sep. 2024Villigen, Aargau, Switzerland- Key results and responsibilities:
• Led and managed multiyear interdisciplinary projects coordinating cross-functional collaboration amongst 3 expert teams and 4 core facilities at 5 locations (ETH, PSI, and as a visiting scientist at the Uni Hospital Basel/Uni Basel, CH; OncoRay, DE).
• Completed preclinical research & development (R&D) of an antibody (Ab)-based biopharmaceutical for novel targeted therapies (target identification; Ab and Ab-based bioconjugate production, characterization, QC; in vitro, in vivo, PK/PD, clinical samples; targeted radionuclide therapy).
• Obtained key clinically relevant insights (biomarkers, cancer stemness, signalling mechanisms, combination treatments). • Regularly communicated internally and externally strategies, results and other insights to stakeholders. • Secured additional funding; - Peer-reviewed publications (4).
• Awarded 2024 Young Scientist Award by the Institute of Pharmaceutical Sciences, ETH Zurich (November 2024). Life Science Zurich Graduate School (Cancer Biology Program); Paul Scherrer Institute (PSI) Center for Life Sciences (Center for Radiopharmaceutical Sciences), ETH Zurich - PSI, Zurich - Villigen PSI, Switzerland
Ludwig-Maximilians-Universität MünchenMentor at the Amgen Scholars Program
Jul. 2019 - Aug. 2019Munich, Bavaria, Germany• Mentored 16 scholars on good scientific practices, bioscience research skills and competencies upon invitation by the program director. • The Amgen Scholars European Program annually hosts 16 selected undergraduate students at LMU (and other European locations) from European universities giving them the opportunity to conduct hands-on research on hot topics in life sciences.
LMU Klinikum MünchenResearch Assistant / Technical Assistant
May. 2019 - Apr. 2020Munich, Bavaria, Germany- Key results and responsibilities:
• Advanced 2 research projects on CAR-T cell-based cancer therapy against solid cancers. • Lab management alongside individual responsibility for 2 laboratories (BSL-1, BSL-2) in a dynamic and multinational team (>50 people).
• Trained 15 medical students on research methods and techniques including designing part of their curriculum (in cell culture, BSL-1). (𝘗𝘳𝘰𝘫𝘦𝘤𝘵𝘴: 1. Investigating anti-HER2 CAR and anti-EGFRvIII CAR T cells with overexpression of CXCR6 (the only known chemokine receptor of CXCL16 secreted by the tumour cells) to enhance tumour infiltration and treatment for breast cancer, and glioblastoma, respectively. 2. Generating and validating a library of CAR T cells overexpressing various chemokine receptors to improve anti-tumour immune responses against multiple cancer types.)
The Babraham InstituteVisiting Scientist, Immunology, Mechanisms of Tolerance and Immunosuppression
Jul. 2018 - Feb. 2019Cambridge, United Kingdom- Key results:
• Established a research methodology for protein overexpression followed by study of immune cells (master transcription factors BACH2 and FOXP3 in regulatory T cells). Currently: Immune Regulation of Inflammation and Cancer (Roychoudhuri Group), Department of Pathology, University of Cambridge, UK.
Ludwig-Maximilians Universität MünchenTranslational Cancer Immunology Research
Nov. 2017 - Jan. 2018Munich, Bavaria, Germany• Project:
- Investigating the blockade of the immune checkpoint receptors PD-1 and LAG-3 in combination with dendritic cell vaccination as an immunotherapeutic strategy against hematologic cancers with low endogenous T cell immune responses.
Ludwig-Maximilians Universität MünchenInnate Immune Mechanisms Research
Feb. 2017 - Apr. 2017Munich, Bavaria, GermanyProjects:
• Investigating the function of diverse pattern recognition receptors (PRRs): NLRs (NLRP3 inflammasome); AIM2 inflammasome; RLRs (RIG-I, MDA-5). • Studying the mechanisms and roles of necroptosis in the crosstalk between cell death and inflammation: the role of the cytokine IL-1 beta in necroptosis-mediated inflammation.
TED ConferencesTED Translator
Dec. 2016 - May. 2024Ideas worth spreading!
Max Planck Institute of BiochemistryScholar, AMGEN Scholars Program, Chaperone-assisted Protein Folding
Jul. 2015 - Sep. 2015Munich, Germany• Project: Successfully established and optimized protein expression and purification to study the interaction between photosynthetic proteins in microorganisms. (Investigating the interaction between the red-type Rubisco enzyme and Rubisco activase through the usage of the chambered proteases ClpXP and ClpAP.) • Selected amongst 150+ applicants to join the program in the group of 20 scholars to obtain hands-on research experience.
Sofia University St. Kliment OhridskiPlant Molecular Biology Research
Sep. 2014 - Jul. 2016Faculty of Biology, Department of Biochemistry, Sofia, BulgariaThesis project: Studying the salinity stress response of common wheat (Triticum aestivum) and the ancient cereal cultivars oriental wheat (Tr. turanicum) and spelt (Tr. spelta)
(Grade: 6/6 according to the Bulgarian grading system in which 6 is the highest and 2 is the lowest grade).
Intch is a Professional Networking App for the Future of WorkSee more people like Tihomir on Intch
300k+ people
130+ countries
AI matching
Get Intch if you'd like to
427561 people
16
Owner/Operator @ Artistry & Hair Design by Jamie Lynn
21
self-employed
15
CMO @ AMTraffic
26475 people
16
Research Associate @ NGO Titian Lestari
15
Associate Professor @ The Bucharest University of Economic Studies
15
Scientist @ NVIDIA